MDH1: A Promising Drug Target and Biomarker for Parkinson's Disease
MDH1: A Promising Drug Target and Biomarker for Parkinson's Disease
Parkinson's disease is a neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia. It affects an estimated 10 million people worldwide, primarily affecting older adults. The underlying cause of Parkinson's disease is the loss of dopamine-producing neurons in the brain, leading to reduced levels of dopamine in the brain. Thus, the search for new treatments and biomarkers is of great importance to understand and alleviate Parkinson's disease.
MDH1: A Candidate Drug Target and Biomarker
The MDH1 gene, which encodes the diiodophenylpyruvate (DOP) reductase enzyme, is a promising drug target and biomarker for Parkinson's disease. As shown in the table below, MDH1 is involved in the production of dopamine, which is a key neurotransmitter involved in motor function.
| System | protein | function |
| --- | --- | --- |
| Cellular Physiology | MDH1 | Diiodophenylpyruvate (DOP) Reductase Enzyme |
| Neurotransmission | dopamine | neurotransmitter involved in motor function |
The Importance of MDH1 in Parkinson's Disease
The loss of dopamine-producing neurons in the brain due to Parkinson's disease is associated with the accumulation of misfolded proteins, including the DJ-1 protein, which is a neurotoxin that leads to the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease. DJ-1 is a protein that is abundant in the brain and has been suggested to contribute to the development and progression of Parkinson's disease.
In addition to its role in dopamine production, MDH1 has also been shown to play a crucial role in the production of other neurotransmitters, including serotonin and noradrenaline. It has been shown to regulate the levels of these neurotransmitters and is involved in the production of neurotransmitters that are critical for normal brain function.
MDH1 as a Biomarker for Parkinson's Disease
The loss of dopamine-producing neurons in the brain is a key feature of Parkinson's disease, and it is associated with the accumulation of misfolded proteins, including DJ-1. The accumulation of misfolded proteins, including DJ-1, is thought to contribute to the development and progression of Parkinson's disease.
MDH1 has also been shown to be involved in the production of other neurotransmitters, including serotonin and noradrenaline. It has been shown to regulate the levels of these neurotransmitters and is involved in the production of neurotransmitters that are critical for normal brain function. Therefore, MDH1 may be a useful biomarker for the diagnosis and assessment of Parkinson's disease.
MDH1 as a Drug Target
The loss of dopamine-producing neurons in the brain due to Parkinson's disease is associated with the accumulation of misfolded proteins, including DJ-1. The accumulation of misfolded proteins, including DJ-1, is thought to contribute to the development and progression of Parkinson's disease.
MDH1 has been shown to play a crucial role in the production of dopamine and other neurotransmitters. Therefore, it is a potential drug target for the treatment of Parkinson's disease. Studies have shown that blocking the activity of DJ-1, the protein that is associated with the misfolding of Parkinson's disease, has the potential to alleviate symptoms of Parkinson's disease.
Conclusion
MDH1 is a promising drug target and biomarker for Parkinson's disease. Its involvement in the production of dopamine and other neurotransmitters makes it a potential target for the treatment of Parkinson's disease. The accumulation of misfolded proteins, including DJ-
Protein Name: Malate Dehydrogenase 1
Functions: Catalyzes the reduction of aromatic alpha-keto acids in the presence of NADH (PubMed:2449162, PubMed:3052244). Plays essential roles in the malate-aspartate shuttle and the tricarboxylic acid cycle, important in mitochondrial NADH supply for oxidative phosphorylation (PubMed:31538237)
The "MDH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MDH1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor | Melanoma-Associated Antigen | Melatonin receptor | MELK | MELTF | MELTF-AS1 | Membrane-Bound Protein Tyrosine Phosphatases (rPTPs) | Membrane-spanning 4-domains subfamily A member 4A | MEMO1 | MEMO1P1 | MEMO1P4
